NervGen Pharma reports Q2 results (OTCMKTS:NGENF)

0


  • NervGen Pharma press release (OTCQB:NGENF): Q2 NervGen had cash and cash equivalents of $26.6 million as of June 30, 2024, compared to $11.7 million as of December 31, 2023.
  • Net loss was $7.8 million ($0.11 loss per basic and diluted common share).



RELATED ARTICLESMORE FROM AUTHOR

LEAVE A REPLY

Please enter your comment!
Please enter your name here